Navigation Links
Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
Date:6/23/2009

AURORA, Ontario, June 23 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) announced today that it has commenced trading in the U.S. on the OTCQX International Market under the ticker symbol HXBPF. Investors can find real-time quotes, disclosure and financial information about the OTCQX International Market at www.otcqx.com.

"Our OTCQX listing provides Helix with enhanced local access to the largest capital market in the world," said John Docherty, president and chief operating officer of Helix. "Following our recently announced 20-F SEC registration, our OTCQX listing is another important steppingstone towards our ultimate goal of a listing on a major U.S. stock exchange such as The NASDAQ."

U.S. investment bank, Merriman Curhan Ford, will serve as Helix's Principal American Liaison ("PAL") on the OTCQX and will be responsible for providing guidance on the Company's continuing OTCQX-listing requirements and arranging a comprehensive suite of U.S. capital market services.

"Merriman is very pleased to sponsor Helix and to serve as their PAL," said Stephen Nash, managing director and head of Merriman Curhan Ford's OTCQX Advisory Group. "With our leadership in the advising, financing and trading of small capitalization health care companies, Merriman is uniquely positioned to help raise this exciting company's profile amongst U.S. investors."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX and FSE under the symbol "HBP" and on the O
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
2. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
3. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
4. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
5. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
6. PDL BioPharma Announces Record Date for October 1 Dividend Payment
7. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
8. SAFE-BioPharma Webinar Featuring ARX's Digital Signatures Combined with Microsoft SharePoint for Bio-Pharma industry
9. Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award
10. The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate
11. SAFE-BioPharma Webinar Featuring ARX's Digital Signature Solution and Adobe LiveCycle Combined Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Carnegie Science Center and Allegheny ... to develop BodyTech, a dynamic, three-pronged health and science ... new exhibit at the Science Center called BodyWorks, the ... traveling science show, Anatomy Adventure, which will hit the ... to explore a wide range of topics surrounding health ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 A ... at the American Society of Clinical Oncology (ASCO)’s ... improved survival rates for those patients who received ... regimen of pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is ... and it is already routinely used to treat ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2
... Pure Power Mouthguard ... , ... December 4, 2009 -- Miami dentist Dr. H.A. Nassery contributes to local athletic ... to patients. He successfully diagnosed and treated Ashley Kimmel, a student at Miami Country Day ...
... 2-D images represent, researchers say , FRIDAY, Dec. 4 ... monkeys they know, proving that they can both detect ... them before, researchers report. , The study also shows ... a photograph, the scientists authors noted. , The findings, ...
... However, benefits are not clear enough to recommend its ... News) -- Cancer patients, glaucoma patients and others can ... shows that it can help multiple sclerosis (MS) patients ... hallmark of the debilitating autoimmune disease. , "The therapeutic ...
... , LOS ANGELES, Dec. 4 Yogen Fruz , the ... holiday themed "NUmixes" -- Yog-Nog and Mint Chocolate ... unveiled at Yogen Fruz stores across North America. Yogen Fruz,s low-calorie ... dessert alternative to indulge in this holiday season. , ...
... , BOSTON and HOUSTON, Dec. 4 AES Annual ... announced today that Vagus Nerve Stimulation (VNS) Therapy , the ... will be featured in 14 presentations at the American Epilepsy ... Hynes Convention Center in Boston, Massachusetts. , Robert Elliott, ...
... , ... InhibOx, a leading developer of novel ... MolPort, an innovator in rare chemical trading.,MolPort focuses on developing rare ... we provide this database and its updates to computational chemists at ...
Cached Medicine News:Health News:Miami Dentist Dr. H.A. Nassery Treats Local Teen Golf Star and Helps Improve Her Performance 2Health News:Review Finds Marijuana May Help MS Patients 2Health News:Review Finds Marijuana May Help MS Patients 3Health News:Yogen Fruz Introduces New Holiday Flavors: Yog-Nog and Mint Chocolate Chip 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 2Health News:NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy 3Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 2Health News:InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery 3
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... -- According to a new market research ... Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species ... Users - Global Forecast to 2020", published by MarketsandMarkets, the ... $736.85 Million by 2020 from $452.36 Million in 2015, ... Browse 71 market data Tables and 90 Figures spread ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... 60 percent of moderate to severe patients achieved ... remission at Week 10,in data from a 54-week ... (ACG) Annual Scientific Meeting, ORLANDO, Fla., Oct. ... prospective study investigating endoscopic improvement in Crohn,s,disease (CD) ...
... Pharmacokinetic Characteristics of Naltrexone SR Associated with ... Better Tolerability in Clinical Trials ... OREX ), a biopharmaceutical company focused on the ... presented,data showing the investigational drug, Contrave(R) (naltrexone SR /,bupropion ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor is a flexible, single-use, minimally ...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The PORTERFIELD catheter incorporates six electrodes which ... from a single catheter. Positioned in the ... while recording atrial electrograms. The catheter may ... apex for atrial recording and ventricular pacing ...
Medicine Products: